ClinicalTrials.gg
CompletedNCT07105540Updated Nov 9, 2026

Comparison of Injection Techniques in Carpal Tunnel Syndrome

A Phase 4 interventional study of 5% Dextrose and Betamethasone and local anesthetic in Carpal Tunnel Syndrome, sponsored by Ankara Etlik City Hospital. Completed at 1 site in Turkey (Türkiye). Open to participants aged 20 Years to 80 Years. Per ClinicalTrials.gov, last updated 2026-11-09.

Sponsored by Ankara Etlik City Hospital · Phase 4, Interventional, and Treatment

How we know

Updated Nov 9, 2026Primary completion movedEnrollment updatedGo to Updates ↓

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 4
Study type
Interventional
Enrollment
46
Allocation
Randomized
Ages
20 Years to 80 Years
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-22

Among 130 studies in Carpal Tunnel Syndrome with a site in Turkey — 36 open to participants now, 41 under way, none of them phase 3. Carpal Tunnel Syndrome · Turkey.

Enrollment
52nd of 82
46 · median 60
Started
2025
with 23 others
Phase 4
5 of 130
none open now
Registered
92nd of 130
by date

Among the 130 studies in Carpal Tunnel Syndrome with a site in Turkey, this one is the 52nd largest by enrollment of the 82 interventional ones that give a count, is one of 24 that started in 2025, is one of 5 in phase 4, and was the 92nd registered.

Carpal Tunnel Syndrome

591 studies on the registry are indexed under Carpal Tunnel Syndrome; 133 are open to participants now.

Browse Carpal Tunnel Syndrome studies →

Open to participants now

36 of the 130 studies in Carpal Tunnel Syndrome with a site in Turkey are open now. Recruiting first, the newest first:

31 more — sign in →

All 36 open studies →

A study can be open while its sites in Turkey have not opened yet or have stopped. Only those recruiting at a site in Turkey →

Who these studies take

Of the 72 Carpal Tunnel Syndrome studies recruiting now, 27 (38%) set no upper age limit and 36 (50%) stop at 75 or younger; 1 takes children under 18; 11 take healthy volunteers.

This study: 20 Years to 80 Years · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 130 studies in Carpal Tunnel Syndrome with a site in Turkey, or all of them as a file.
02

Study summary

The aim of this study is to compare the effects of ultrasound-guided hydrodissection with 5% dextrose and perineural corticosteroid injection on the clinical parameters of carpal tunnel syndrome, as well as to evaluate the long-term efficacy of these treatments.

Read the detailed description

Carpal tunnel syndrome (CTS), the most prevalent peripheral compressive neuropathy, manifests primarily with sensory disturbances such as pain, numbness, and nocturnal paresthesia. Treatment options for CTS differ considerably depending on the severity of symptoms, and typically include splinting, physiotherapy, local injection therapies, and surgical release. Hydrodissection is an ultrasound-guided technique that has recently gained increased attention for its role in the management of nerve entrapment syndromes. The technique uses fluid injection to separate the nerve from nearby tissues. This may reduce perineural adhesions and improve the patient's symptoms. In hydrodissection, normal saline, 5% dextrose, or platelet-rich plasma (PRP) can be used as injectates. Recently, hydrodissection with 5% dextrose has become the most commonly used approach. Several studies in the literature have demonstrated that perineural hydrodissection with 5% dextrose provides more favorable outcomes than corticosteroid injections in patients with mild to moderate CTS, particularly at 4 to 6 months post-injection. However, it remains unclear whether hydrodissection leads to a reduction in the cross-sectional area of the median nerve. In addition, studies examining the procedural details of hydrodissection are limited. Therefore, further clinical research is needed to better understand and validate the technique.

Ultrasound-guided hydrodissection for CTS is performed using a 12 MHz linear array transducer probe (GE Logiq P9, GE Healthcare, Boston, MA). The median nerve (MN) is visualized at the scaphoid-pisiform level. In the intervention group, 2.5 ml of 5% dextrose is injected via an in-plane ulnar approach to separate the MN from the transverse carpal ligament, followed by an additional 2.5 ml of normal saline (NS) injected to separate the MN from the flexor tendons. In the control group, perineural injection of 1 ml betamethasone is administered around the MN using the same ultrasound device and probe.

03

Conditions studied

  • Carpal Tunnel Syndrome

Keywords

  • Hydrodissection
  • Perineural Injection
  • Median Nerve
04

Who can participate

Ages eligible
20 Years to 80 Years
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Patients diagnosed with unilateral moderate carpal tunnel syndrome (CTS) confirmed by an electrophysiological study within the last 6 months
  • Presence of at least one of the following symptoms lasting more than one month:

    • Paresthesia/dysesthesia accompanied by weakness and clumsiness in the hand, worsened by repetitive wrist use or sleep, and relieved by postural correction or shaking of the hand
    • Numbness due to sensory disturbance in the median nerve (MN) distribution
    • Thenar muscle weakness with atrophy
    • Positive Tinel's sign or Phalen's test
  • Pain intensity of ≥4 out of 10 on the Visual Analog Scale (VAS) prior to treatment

Exclusion criteria

Exclusion Criteria:

  • History of previous wrist surgery, polyneuropathy, brachial plexopathy, or thoracic outlet syndrome
  • Presence of systemic infection
  • Pregnancy
  • Prior injection for CTS
Terms in these criteria, in plain language(1)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Corticosteroids (steroids)

Anti-inflammatory medicines such as prednisone, prednisolone and dexamethasone — not the anabolic steroids used for muscle.

Studies differ in what they allow: check which steroid medicines, routes (tablets, injections, creams, inhalers, eye drops) and doses this study accepts.

05

Study design

Phase
Phase 4
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
Single (Outcomes assessor)
Enrollment
46 participants (actual)

Study arms

  • Active comparator
    Hydrodissection group

    Participants in the hydrodissection group will undergo ultrasound-guided perineural hydrodissection of the median nerve at the scaphoid-pisiform level using a 12 MHz linear transducer (GE Logiq P9, GE Healthcare, Boston, MA). Under sterile conditions, 2.5 ml of 5% dextrose will be injected via an in-plane ulnar approach to mechanically separate the median nerve from the transverse carpal ligament. Subsequently, an additional 2.5 ml of 5% dextrose will be administered to separate the nerve from adjacent flexor tendons. The total injection volume will be 5 ml.

    Drug: 5% Dextrose

  • Active comparator
    Corticosteroid group

    Participants in the corticosteroid group will undergo ultrasound-guided perineural injection of the median nerve at the scaphoid-pisiform level using a 12 MHz linear transducer (GE Logiq P9, GE Healthcare, Boston, MA). A perineural injection of 1 ml betamethasone combined with 1 ml 2% lidocaine will be administered around the median nerve.

    Drug: Betamethasone and local anesthetic

Interventions

  • DrugGlucoseStudies of GlucoseGlucose pageHow we knowJudged by ClinicalTrials.gg, not part of the registry record.

    Ultrasound-guided hydrodissection is performed using a 12 MHz linear transducer (GE Logiq P9, GE Healthcare) via an in-plane ulnar approach under sterile conditions. 2.5 ml of 5% dextrose will be injected via an in-plane ulnar approach to mechanically separate the median nerve from the transverse carpal ligament. Subsequently, an additional 2.5 ml of 5% dextrose will be administered to separate the nerve from adjacent flexor tendons. The total injection volume will be 5 ml.

  • DrugBetamethasone and local anesthetic

    Drug pages: BetamethasoneStudies of BetamethasoneBetamethasone pageHow we knowJudged by ClinicalTrials.gg, not part of the registry record. · Local anestheticsStudies of Local anestheticsLocal anesthetics pageHow we knowJudged by ClinicalTrials.gg, not part of the registry record.

    Ultrasound-guided perineural injection is performed using a 12 MHz linear transducer (GE Logiq P9, GE Healthcare) via an in-plane ulnar approach under sterile conditions. A total of 2 ml solution (1 ml betamethasone and 1 ml 2% lidocaine) is injected perineurally around the median nerve under ultrasound guidance at the scaphoid-pisiform level.

06

What researchers measure

Primary outcomes

  1. Boston Carpal Tunnel Questionnaire

    The Boston Carpal Tunnel Questionnaire (BCTQ) is a validated disease-specific assessment tool developed in 1993 to provide standardized clinical evaluation of carpal tunnel syndrome (CTS). It comprises 19 items divided into two subscales: the Symptom Severity Scale (BCTQ-SSS) and the Functional Status Scale (BCTQ-FSS). Scores on both subscales range from 1 to 5, with higher scores reflecting increased symptom burden and functional impairment associated with CTS.

    Time frame: At baseline, at Month 1,3,6 (Visit 1,2,3)

Secondary outcomes

  1. Visual Analog Scale (VAS)

    Patients rate their pain on a 0-10 scale. A lower score indicates reduced pain.

    Time frame: At baseline and at Month 1,3,6 (Visit 1,2,3)

  2. Cross-Sectional Area (CSA) of the Median Nerve via Ultrasonography

    Median nerve CSA will be measured at the scaphoid-pisiform level. A reduction in CSA indicates improvement.

    Time frame: At baseline and at month 3,6 (Visit 2,3)

  3. Hand Grip Strength

    Hand grip strength will be measured using a standard Jamar dynamometer. During the procedure, patients will be seated with the elbow flexed at 90° and the forearm in a neutral position. Three consecutive measurements will be taken, and the average value will be recorded. Improvement reflects functional recovery.

    Time frame: At baseline and at Month 3,6 (Visit 2,3)

07

Study locations

1 site
  • Etlik City Hospital
    Ankara, Yenimahalle 06370, Turkey (Türkiye)
08

References and documents

Individual participant data

Plan to share: No

No publications or documents are linked to this record.

09

Timeline

1 registry update since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedDate before it movedWhere the date was before it movedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Ran from Aug 2025 to primary completion in Mar 2026, 7 months.

Of 28 non-industry phase 4 interventional studies under Carpal Tunnel Syndrome, half reached primary completion within 7 months of starting (the median), counting those still running; a quarter within 3 and three quarters within 19. This study's 7 months is close to that.

Counting every sponsor, half of 28 studies reached it within 7 months; a quarter within 3 and three quarters within 19.

Primary completion moved once since we started tracking on Sep 25, 2026: Feb 2026 → Mar 2026, on Nov 9, 2026.

Earlier changes are on the record history on ClinicalTrials.gov ↗

How these figures are worked out, and which studies are left out of them.

Registered
Jul 14, 2025
First posted
Aug 6, 2025
StartActual
Aug 5, 2025
Primary completionActual
Mar 30, 2026was Feb 2026
CompletionActual
Mar 30, 2026
Last update
Nov 9, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
Primary completion
Feb 5, 2026→Mar 30, 2026
Nov 9, 2026
Enrollment
53→46
Nov 9, 2026
Show all 1 update
  1. Nov 9, 2026
    Primary completion Feb 5, 2026→Mar 30, 2026
    Enrollment 53→46

From the registry record's own update history. This site started tracking changes on Sep 25, 2026; for anything earlier, see the record history on ClinicalTrials.gov ↗

10

Registry details

Key details

Study ID
NCT07105540
Responsible party
Gizem Suna Tuncer (Principal Investigator, Physical Medicine and Rehabilitation Specialist, Ankara Etlik City Hospital) — Principal investigator
First posted
Aug 6, 2025
Start date
Aug 5, 2025
Primary completion
Mar 30, 2026
Completion
Mar 30, 2026
Last update
Nov 9, 2026

Oversight

Data monitoring committee
No
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Apr 2026. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drugs tested here: Glucose · Betamethasone · Local anesthetics

Start the discussion